Scholar Rock Holding Corporation
HealthcareNASDAQ:SRRK · NASDAQ Global Select
-$0.51 today
Vol 1.15M · Avg 1.45M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$408.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.45, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 -100.0% | $33.2M +76.4% | $18.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 -100.0% | $1.9M -31.9% | $2.8M -97.7% | $123.0M +13.4% | $108.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 +100.0% | -$1.9M +31.9% | -$2.8M +96.8% | -$89.9M -0.2% | -$89.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | -270.7% +205.8pp | -476.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $208.4M +14.1% | $182.6M +53.4% | $119.1M -4.3% | $124.4M +14.7% | $108.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $176.2M +161.0% | $67.5M +36.7% | $49.4M +15.9% | $42.6M +5.8% | $40.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $384.6M +53.8% | $250.1M +48.5% | $168.5M +278.4% | $44.5M +10.6% | $40.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.7M -14.4% | $1.9M -31.9% | $2.8M -4.8% | $3.0M +13.7% | $2.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$369.4M -55.5% | -$237.5M -45.8% | -$162.9M -25.8% | -$129.5M -0.2% | -$129.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | -390.1% +296.4pp | -686.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$384.6M -52.6% | -$252.1M -47.1% | -$171.3M -27.5% | -$134.4M -3.4% | -$129.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | -404.8% +285.7pp | -690.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $13.9M +9.6% | $12.7M | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $6.9M +0.8% | $6.8M | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $6.7M +16.4% | $5.8M +4.6% | $5.5M +4271.2% | -$132.0K +93.0% | -$1.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$377.9M -53.5% | -$246.3M -48.6% | -$165.8M -23.3% | -$134.5M -2.1% | -$131.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | -405.2% +295.3pp | -700.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$377.9M -53.5% | -$246.3M -48.6% | -$165.8M -23.3% | -$134.5M -2.1% | -$131.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | -405.2% +295.3pp | -700.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 -33.2% | -$2 -24.1% | -$2 +10.0% | -$2 +38.4% | -$4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 -33.2% | -$2 -24.1% | -$2 +10.0% | -$2 +38.4% | -$4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $114.7M +14.9% | $99.8M +31.4% | $76.0M +27.5% | $59.6M +62.4% | $36.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $114.7M +14.9% | $99.8M +31.4% | $76.0M +27.5% | $59.6M +62.4% | $36.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.63B
Cidara Therapeutics, Inc.
CDTX
$5.61B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.11B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$3.90B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SRRK generate?
Scholar Rock Holding Corporation (SRRK) reported $0.00 of revenue in fiscal 2025.
Is SRRK profitable?
Scholar Rock Holding Corporation (SRRK) reported -$377,939,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.